Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "iNGEN"

218 News Found

Defending Public Health: Strategies to safeguard pharmaceutical quality: Raheel Shah, Business Development Director, BDR Pharmaceuticals
Opinion | September 08, 2023

Defending Public Health: Strategies to safeguard pharmaceutical quality: Raheel Shah, Business Development Director, BDR Pharmaceuticals

This exposé embarks on an illuminative journey, unfurling the crucial stratagems imperative for upholding public health, achieved through the unyielding fortress of pharmaceutical quality safeguards


Mankind Pharma launches 120 premium DMF quality drugs for Indian Patients
News | August 30, 2023

Mankind Pharma launches 120 premium DMF quality drugs for Indian Patients

Mankind Pharma's initiative aims to ensure universal access to medicines of international calibre


LEO Pharma to acquire Timber Pharmaceuticals
News | August 22, 2023

LEO Pharma to acquire Timber Pharmaceuticals

The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million


Pfizer receives USFDA approval for Elrexfio for the treatment of relapsed or refractory multiple myeloma
Drug Approval | August 16, 2023

Pfizer receives USFDA approval for Elrexfio for the treatment of relapsed or refractory multiple myeloma

ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity


NMPA approval for first BCMA CAR-T Therapy paves way for more multiple myeloma cell therapies, says GlobalData
Drug Approval | July 11, 2023

NMPA approval for first BCMA CAR-T Therapy paves way for more multiple myeloma cell therapies, says GlobalData

Approval to dramatically change CAR-T therapies landscape


CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals
News | July 05, 2023

CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals

The 'A+' rating reflects IOL's robust business model, diversified product portfolio


USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma
Drug Approval | June 19, 2023

USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma

Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma